glp 1 drugs and menopause Women turn to weight loss in menopause: What to know about the benefits risks GLP-1 weight loss drugs could
Description
both produce large, clinically meaningful weight loss in human trials
However, as polypeptide drugs, GLP-1RAs are easily hydrolyzed by enzymes in the gastrointestinal environment
This translated into the strong recommendation of the European Society of Cardiology on the use of GLP-1 RAs in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD) in 2019 [73]
In a landmark development, liraglutide (Saxenda) was approved in 2020 for use in adolescents aged 12-17 years with a body weight above 60 kg and an initial BMI corresponding to 30 kg/m for adults [17]
